5PSQ-080 Effectiveness and security of alemtuzumab in relapsing-remitting multiple sclerosis

BackgroundAlemtuzumab is a humanised monoclonal antibody that selectively targets CD52, resulting in depletion and subsequent distinct repopulation of circulating T and B lymphocytes.PurposeTo evaluate the effectiveness and security of alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis (RRMS).Material and methodsRetrospective and observational study between December 2014 and November 2017 of patients diagnosed with RRMS after 1 year of treatment with alemtuzumab.Variables collected: age, sex, years with RRMS diagnosis, Extended Disability Status Scale (EDSS), percentage of patients without outbreaks and outbreaks/patient-year, previous treatments and adverse drug reactions (ADRs).The effectiveness of treatment was assessed by calculating annualised relapse rates(ARRs) and change in disability status by EDSS. Change in disability was defined according to criteria of Fernández et al. that defined improvement as any decrease ≥1 point, stabilisation as any change 90%, being mild to moderate in severity and generally included headache, rash, pyrexia, nausea, flushing, urticaria, insomnia and pruritus. Also,>10% of patients showed cardiac disorders, in particular tachycardia.References and/or Acknowledgements1. Fernández O, et al. Natalizumab treatment of multiple sclerosi